Guggenheim initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $20 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- 3 Stocks Flashing Strong Buy Signals on Technical Charts
- Adaptive Biotechnologies: Strategic Shift and Financial Realignment Support Buy Rating
- Adaptive Biotechnologies: Strategic Flexibility and Robust MRD Growth Drive Buy Rating
- Adaptive Biotechnologies down 5% after Genentech pact terminated
- Adaptive Biotechnologies: Strategic Flexibility and Innovation Drive Buy Rating